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Abstract. In pulmonary sarcoidosis an activation of alveolar T lymphocytes and alveolar macrophages (AM) 
has been demonstrated. There is evidence that in contrast to acute disease a heightened T-cell response cannot 
be observed in the chronic phase of sarcoidosis. The role of A M in the inflammatory process of chronic sarcoi-
dosis is not yet intensively evaluated. To address this question we measured the release of tumor necrosis factor 
alpha (TNFct) and interleukin-1 (IL-1) by A M of 39 patients with chronic sarcoidosis (duration >4 years; 30 ac-
tive, 9 inactive diseases) without therapy and correlated the monokine release with parameters of T-cell alveo-
litis and the course of the disease. The T4/T8 ratio was higher in the active than in the inactive group without 
reaching statistical significance. T N F a as well as IL-1 is spontaneously released by A M of the active group 
2,099 ±518 pg/ml TNFct/106 cells/24 h and 8/13 (IL-l+/total) respectively. In the inactive group the A M release 
375 ± 246 pg/ml TNFct/106 cells/24 h which is in the range of the control and 1 out of 5 patients was IL-l-positive. 
There was no correlation between the monokine release and any parameter of T-cell alveolitis. These data sup-
port the hypothesis that the inflammatory process in chronic sarcoidosis is dominated by the activity of A M and 
that this activity determines the course of the disease. 
Introduction 
Sarcoidosis is a systemic granulomatous disorder 
of unknown origin characterized by a T-lymphocyte/ 
alveolar macrophage (AM) alveolitis, granuloma for-
mation and distortion of the normal architecture of 
the lower respiratory tract [1-3]. The lung is the most 
commonly involved organ [4, 5], and studies with lung 
inflammatory cells recovered by bronchoalveolar lav-
age (BAL) revealed an activation of A M and alveolar 
T lymphocytes [1-7]. In sarcoidosis both cell types 
spontaneously release immunoregulatory substances 
(e.g. interleukin (IL)-l, tumor necrosis factor alpha 
(TNFa), interferon (INF)-gamma, IL-2, monocytic 
chemotactic factor and soluble interleukin-2 receptor 
(sIL-2R) [6-14]) and express activation markers on 
their cell surface [15-17]. In most studies the patients 
are grouped according to those criteria of inflamma-
tion resulting in groups of patients with inflammatory 
active or inactive disease. However, from a clinical 
point of view there are two different kinds of sarcoi-
dosis with completely different characteristics: acute 
and chronic disease which is not considered by this 
way of staging [18, 19]. 
There is a clear association between the activity of 
the disease and the numbers, types and functions of T 
lymphocytes that are found in the alveolitis [5,11,17 
19-21]. A M have not been evaluated as extensively & 
Table 1. Clinical and physiological characteristics of the study 
population 
Active Inactive 
sarcoidosis sarcoidosis 
Clinical data 
Patients, n 30 9 
Age, years 44.7 ±2.7 44.1 ±3.7 
Male/female 15/15 6/3 
Smoker/nonsmoker 8/30 3/9 
Pulmonary function test 
V C 1 75.5 ±3.4 89.8 ±7.4 
F E V 1 1 96.1 ±4.0 79.7 ±7.1 
R t o t 0.24 ±0.03 0.25 ±0.03 
V C = Vital capacity; FEV1 = forced expiratory volume in 1 s; 
R t o t = total pulmonary resistance. 
1 Expressed as percent predicted. 
lung T cells in terms of the pathogenesis of the dis-
order. However, it is likely that these cells are an im-
portant component of the immunopathogenesis of 
sarcoidosis, because they comprise the majority of the 
alveolar inflammatory cells and (b) because they are 
capable of providing accessory signals required for T-
cell activation [22, 23]. 
We performed a simultaneous anaylsis of the activ-
ity of A M as well as of alveolar T cells in chronic sar-
coidosis. To accomplish this, the capacity of A M to re-
lease T N F a and IL-1 was evaluated and the surface 
expression of activation markers of alveolar T cells 
was quantified. 
Patients and Methods 
Study Population. The diagnosis of sarcoidosis was established 
in 39 individuals using defined criteria, including transbronchial 
biopsy [4]. A l l patients suffered from chronic disease with persist-
ing or undulating clinical signs of inflammation of a minimal dura-
tion of 4 years. None of them was receiving therapy at the time of 
investigation or within the previous 2 months. For the purpose of 
-his study the patients were grouped as having 'clinically active 
sarcoidosis' or 'clinically inactive sarcoidosis' based on clinical cri-
teria, i.e. new or progressing pulmonary symptoms - such as cough 
^nd dyspnea - radiographic abnormalities, or systemic symptoms. 
There were 30 patients in the clinically active and 9 in the clinical-
y inactive group. The two groups did not differ by age, sex, pul-
monary function test or smoking history (p > 0.2, for all compari-
sons) (table 1). Seven patients who were bronchoscopized for di-
agnostic reasons and were free of interstitial lung disease 
retrospectively or had benign neoplasia, served as controls. 
Preparation of Lung Mononuclear Cells. B A L was performed by 
flexible fiberoptic bronchoscopy with a total volume of 200 ml of 
0.9% sterile saline in four 50-ml aliquots. The original description 
[24] was slightly modified. The differential cell counts were per-
formed on Wright's stained cytocentrifuge preparations. For sub-
sequent use, the cells recovered were washed 3 times in R P M I 
1640 (Gibco, Wiesbaden, F R G ) , and were resuspended in tissue 
culture medium. Pure A M (> 98% pure) were prepared by Ficoll-
Hypaque density gradient centrifugation [25] and subsequent 120 
min plastic adherence at 4°C. 
Tissue Culture. The A M were cultured over a period of 24 h 
without any additives, or in the presence of either 1 jig/ml lipopo-
lysaccharide (LPS) (Escherichia coli, serotype: 055:B5; Sigma, 
Miinchen, F R G ) or 10 6M prednisolone (Sigma) or both at a densi-
ty of 106 cells/ml in R P M I 1640 supplemented with endotoxin-free 
10% Nu serum (Flow Laboratories, Meckenheim, F R G ) , 2 mAf 
glutamine (Gibco), 100 U/ml penicillin (Gibco) and 100 jig/ml 
streptomycin (Gibco) 24-well tissue culture plates (Nunc, Wies-
baden, F R G ) in 5% C 0 2 humidified atmosphere at 37 °C. At the 
end of the culture period the supernatants were harvested and 
stored at -20 °C until they were tested for T N F a and IL-1 activity. 
TNFa Assay. T N F a was determined by an enzyme-linked im-
munosorbent assay (ELISA) as described [27] with some mod-
ifications: Briefly, 96-well flat-bottom plates (Titertek Immuno 
Assay-Plate, Flow Laboratories) were coated with monoclonal an-
ti-recombinant human T N F a (rhTNFa) antibody (clone 195; kind-
ly provided by Dr. E. Schlick, Knoll A G , Ludwigshafen, F R G ) 5 
ug/ml in N a H C 0 3 buffer (0.05 M, p H 9.0) for 16 h at 4°C. Serial 
dilutions of the test samples in phosphate buffer (0.1 M , p H 7.5, 
2% EDTA, 1% bovine serum albumin (BSA)) were applied to the 
plates for 2 h at room temperature after the wells had been 
blocked with 1% BSA in phosphate-buffered saline (PBS) for 2 h 
at room temperature. Plates were washed with PBS containing 
0.05% Tween and 2.7 jig/ml biotin (Sigma)-conjugated affinity pu-
rified (Protein A-Diasorb) polyspecific rabbit anti-rhTNFa anti-
bodies were added to the wells for 1.5 h at room temperature. Af-
ter extensive washing with PBS containing 0.05% Tween streptavi-
din-peroxidase complex (Boehringer Mannheim, F R G ) at a 
dilution of 1:10,000 was applied for 30 min at room temperature. 
The plates were washed again and the substrate solution (10 mg 
1,2-phenyldiamine (OPD; Sigma) in 10 ml acetate-citric acid buff-
er (0.1 M, pH 4.9) and 20 ul 3% H 2 0 2 ) was added to the complex. 
The reaction was stopped with 2 M H 2 S 0 4 , and absorption was 
measured at 492 nm. The absorption curves obtained with the test 
samples were compared with a standard curve obtained with 
rhTNFa (kindly provided by Dr. E. Schlick, Knoll A G ) and the 
T N F a content expressed as pg/ml. 
IL-1 Activity. IL-1 activity was determined by the conventional 
costimulator assay [28]. In brief, single cell suspension of C3H/ 
HeJ thymocytes (5 x 105 cells/culture) were cultured in the pres-
ence of phytohemagglutinin ( P H A - M , 5 ug/ml, Sigma) and serial 
dilutions of the test samples for 3 days. The culture was pulsed 
with 1 uCi tritiated thymidine ((6-3H)thymidine, specific activity 
50 Ci/mM; Amersham Buchler, Braunschweig, F R G ) for 6 h and 
incorporated counts were determined. IL-1 titers are given as the 
final dilutions of the supernatants which cause cpm 2.5-fold higher 
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Fig. 1. Spontaneous (A), LPS-stimulated (1 ug/ml) (B) and 
prednisolone-inhibited (10 - 6 M) T N F a release by 106 A M of pa-
tients with active and inactive chronic sarcoidosis and of the con-
trol group. The horizontal bars indicate the mean. 
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Fig. 2. Spontaneous (A), LPS-stimulated 1 |ig/ml (B) and pred-
nisolone-inhibited (10 - 6 M) IL-1 activity of A M of patients with ac-
tive and inactive chronic sarcoidosis. 
than background. Control experiments demonstrated that the ad-
dition of the tissue culture aadditives (LPS, prednisolone) in the 
concentration applied did not influence this assay. 
Monoclonal Antibodies and Staining Procedure. Cells were 
stained with unconjugated monoclonal antibodies directed against 
CD3, CD4, CD8, H L A - D R (Becton-Dickinson, Heidelberg, FRG) , 
CD25, CD16 (Ortho Diagnostic Systems GmbH, Neckargemund, 
F R G ) , and VLA-1 (T-Cell Sciences, Cambridge, Mass., USA) at a 
concentration suggested by the suppliers. Cells were fixed on poly-
lysine-coated slides, and developed with an immunoperoxidase 
technique [29]. 
Statistical Methods. A l l comparisons were made by using either 
the two-tailed Student's t test or the Mann-Whitney U test. The 
comparisons of the distributions of sex and smoking history of the 
study population were done by using %2 t e s t - A l l data are ex-
pressed as mean ± standard error of the mean (SEM). 
Results 
T-Cell Activation Markers. In B A L of patients with 
active sarcoidosis a considerable increase of total cells 
recovered (20.8 ±3.9 vs. 12.7 ± 3.8 x 106/100 ml recov-
ered B A L ) and an increase in the CD4/CD8 ratio (3.8 
vs. 2.7) can be observed. However, there is only a mar-
ginal increase in the percentage of B A L lymphocytes 
in active disease (21.5 ±2.4 vs. 14.8 ±3.3%) (p <0.05) 
(table 2). Both groups of patients exhibit a slight ele-
vation in the expression of H L A - D R , IL-2R, CD16, 
and VLA-1 by B A L lymphocytes without any signif-
icant difference between active and inactive disease. 
In relationship to the reported alterations in acute 
disease the increase of the CD4/CD8 ratio as well as 
the expression of the activation markers is only mod-
erately elevated. 
TNFa Release. A M of patients with active sarcoido-
sis spontaneously release T N F a in considerable 
amounts (2,099 ±518 pg/ml). In marked contrast, A M 
of patients with inactive sarcoidosis release much low-
er quantities (375 ± 246 pg/ml) which are in the range 
of the background of the assay and do not differ from 
control (261 ±86 pg/ml; p > 0.2) (fig. 1A). Concerning 
the spontaneous T N F a release, the inactive group 
and the control differ significantly from active disease 
(p < 0.002 in both comparisons). Stimulation of the 
A M with LPS results in a heightened monokine pro-
duction in all three groups (22,906 ±3,011 pg/ml in ac-
tive, 9,738 ±2,240 pg/ml in inactive disease, and 
17,189 ±3,671 pg/ml in the control group) (fig. IB). 
The difference between active and inactive disease is 
of statistical significance (p < 0.05). 10 - 6 M predniso-
lone notably inhibited the spontaneous T N F a release 
(80% suppression in the active group) (fig. 1A). The 
LPS-stimulated TNFa release as well is considerably 
reduced in both groups by the addition of predniso-
lone (fig. IB). 
IL-1 Release. The results obtained with the IL-1 as-
say parallel the findings described for TNFa. In the 
active group a substantial spontaneous IL-1 release 
(62% of the patients) which is sensitive to predniso-
lone can be observed (fig. 2). The LPS-stimulated IL-1 
release of these A M is markedly reduced by pred-
nisolone resulting in a 2-fold lower average titer of 
the positive samples. In the inactive group in 4 out of 
5 patients no spontaneous IL-1 release can be found. 
In only 1 out of 5 patients tested, an activity above the 
background range of the assay at the lowest possible 
dilution of 1:4 was observed. In this group as well the 
LPS-stimulated IL-1 release was inhibitable by pred-
nisolone. 
Discussion 
The presented analysis demonstrates (a) that in 
chronic sarcoidosis the spontaneous monokine re-
lease segregates well with the activity of the disease, 
(b) that this A M activity can be suppressed by in vitro 
application of corticosteroids, and (c) that signs of 
T-cell activation do not parallel the functional activity 
of A M . 
Table 2. B A L cells characteristics of patients with active and 
inactive sarcoidosis 
Active Inactive 
sarcoidosis sarcoidosis 
Total cells counts1 20.8 ±3.9 12.7 ±3.8 
A M , % 77.5 ±2.4 84.1 ±3.5 
Neutrophils, % <2 <2 
Lymphocytes, % 21.5±2.4 a 14.8 ±3.3 
cm 9 2 . 1 ± l . l b 83.6 ±3.2 
CD4 68.5±3.1 c 54.5 ±4.4 
CD8 25.2 ±3.0 28.8 ±4.0 
CD4/CD8 3.8 ±0.8 2.7 ±0.9 
H L A - D R 15.8 ±2.1 12.5 ±2.5 
CD25 5.5 ±0.5 4.8 ±1.3 
CD16 1.9 ±0.6 0.7 ±0.2 
VLA-1 7.9 ±1.4 7.8 ±1.6 
a p < 0.05; b p < 0.005; c p <0.03. 
x 10^  in 100 ml B A L recovered. 
Our findings are in conflict - regarding the T-cell 
segment of the alveolitis - with some previously pub-
lished reports of exaggerated T-cell activity in sarcoi-
dosis [30-34], To the best of our knowledge there are 
no studies available focusing on the alveolitis of the 
chronic form of the disease. Greenings et al. [35] re-
ported a decrease of B A L lymphocytes in correlation 
to the duration of the disease and Hollinger et al. [36] 
demonstrated that patients with inflammatory active 
sarcoidosis and low numbers of B A L lymphocytes 
have a high risk of treatment failure and subsequent 
development of chronic disease. The wide range of al-
terations in T-cell alveolitis found in the literature 
may be due to the amalgamation of patients with 
acute and chronic disease in groups with active and 
inactive sarcoidosis [15, 16, 21, 30-33]. 
A M and monocytes are known to differ in their ca-
pacities to release monokines. A M release more 
TNFa and less IL-1 than an equal number of mono-
cytes [37]. It is feasible to assume that in sarcoidosis 
the inflammatory milieu of the lower respiratory tract 
activates the A M resulting in the release of mono-
kines, T N F a as well as IL-1 have been reported to be 
present in the alveolitis of sarcoidosis [7, 8, 38-40]. 
Here we additionally demonstrate that the spontane-
ous monokine release segregates with the clinical ac-
tivity of the disease and that the pathological findings 
of functional A M activity are dominating the alveo-
litis of chronic sarcoidosis. The observation of only 
marginal alterations regarding the T-lymphocytic al-
veolitis is in accordance with the fact of reduced per-
centages of B A L lymphocytes in chronic disease. 
Using the thymocyte proliferation assay, Hunning-
hake [7] and ourselves could find sarcoidosis patients 
with IL4-positive A M . Employing the same method 
this could not be found by Kleinhenz et al. [38] and 
Eden and Turino [39]. On the mRNA level, IL-1- and 
TNFa-positive A M could be found [40]. Recently, 
Spatafora et al. [41] demonstrated a heightened T N F a 
release after LPS stimulation of mononuclear cells of 
patients with active sarcoidosis. Here we confirm and 
extend this observation. In the active group a height-
ened LPS-induced and a considerable spontaneous 
T N F a release could be observed. As reported by Spa-
tafora et al. regarding the stimulated release, the dif-
ference between active and inactive disease is of sta-
tistical significance. Additionally, we could clear-cut 
demonstrate a spontaneous T N F a release by A M of 
the active group. This activity is well beyond the low 
levels of T N F a release by A M of the inactive and the 
control group respectively. In contrast to our study, 
Spatafora et al. used different experimental condi-
tions for A M stimulation and a cytotoxic bioassay for 
the evaluation of TNFa. The experimental differences 
in combination with different patient populations and 
control groups might well account for the differences 
in these observations. 
Wewers et al. [42], however, demonstrated IL-1 
mRNA-negative A M in a large group of sarcoidosis 
patients with a highly active alveolitis. Several facts 
could explain these apparently contradictory results. 
The thymocyte proliferation assay can easily be ham-
pered by immunosuppressive compounds present in 
the test samples, e.g. inhibitors binding IL-1 or block-
ing receptors transducing the mitogenic signals [43, 
44]. The activation threshold to release monokines is 
linked to class II genes [45]. This may result in differ-
ent IL-1 and IL-1 m R N A levels in study populations of 
different ethnical composition. 
In in vitro experiments T N F a and IL-1 are usually 
coexpressed [43], thus the in vivo coexpression at the 
m R N A as well as the protein level can be expected. 
The two genes are only transcribed over a short peri-
od of time after stimulation followed by a long refrac-
tory period. Thus, only few cells in B A L can be ex-
pected to transcribe the genes and to release the 
monokines. In this context the different regulation of 
the two genes might be of relevance. The predom-
inantly posttranscriptional regulation of IL-1 may re-
sult in an immediate decay of the mRNA in the ex vi-
vo situation [46]. 
Our findings have some implications for the cur-
rent concept of the immunopathogenesis of sarcoido-
sis: 
(a) Acute and chronic disease differ substantially 
in the characteristics of their alveolitis with a dom-
inance of T cells in acute and a dominance of A M in 
chronic disease. Thus, the alveolitis of chronic sarcoi-
dosis is characterized by a moderate increase in the 
percentage of T cells and an accumulation of func-
tionally activated A M . Consequently, new staging sys-
tems should include parameters of A M activity, es-
pecially in the evaluation of patients with chronic 
disease. 
(b) T N F a and IL-1 are products of A M which are 
able to stimulate these macrophages [47-50]. This 
heightens the possibility of the maintenance of the in-
flammation of chronic disease by an autocrine stim-
ulation of A M [49]. Such a mechanism of stimulation 
has been demonstrated in in vitro systems for mono-
cytic cells [48] as well as for T lymphocytes [51]. 
(c) A monocyte influx to the alveoli and a local 
proliferation of A M have been observed in sarcoido-
sis [52]. Besides the known chemoattractants released 
by sarcoid T cells T N F a is also chemotactic for mono-
cytes from the peripheral blood [50] resulting in an 
additional mechanism of monocyte accumulation in 
the alveoli. 
(d) IL-2 release is a critical feature of the T-cell al-
veolitis. Sarcoid A M are known to express the IL-2 re-
ceptor and IL-2 is able to stimulate T N F a release by 
monocytes [53]. Thus the T-cell and the A M segment 
of the sarcoid alveolitis might influence each other 
and the T-cell alveolitis might up-regulate the A M ac-
tivity resulting in chronic disease. 
(e) In inactive disease the spontaneous as well as 
the LPS-stimulated monokine release are markedly 
lower than in active disease. The high LPS response is 
a consequence of the long-lasting in vivo preactiva-
tion of the A M which is known to induce an exagger-
ated monokine release by macrophages [38]. It is con-
ceivable that this preactivation is delivered by the 
unknown etiological agent of sarcoidosis. Activated 
macrophages release the monokines tested only over 
a short period of time after stimulation [37]. Conse-
quently, the activation must have taken place in the 
hours preceding the B A L and the stimulating agent 
has to reside in the alveoli, as it has been suggested 
for the T-cell activation in the course of sarcoidosis. 
The decrease in the LPS response as well as the quies-
cent A M in inactive disease give evidence that the un-
derlying processes maintaining the inflammation are 
overcome. However, there is still no clear-cut evi-
dence if this stimulating process is based on a nominal 
antigen or an immunodysregulation. The result of 
such an immunodysregulation could be the exaggerat-
ed accessory activity of sarcoid A M . The observed 
A M activation is compatible with both possibilities. 
(f) The administration of corticosteroids is in gen-
eral of clinical benefit and limits the inflammatory 
symptoms of sarcoidosis. This might well be a sequela 
of its impact on the inflammatory activity of macro-
phages, because corticosteroids are known to sup-
press the monokine release and the accessory func-
tions of these cells [54]. The cachectic effect of TNFa 
which is a possible cause of the clinical symptoms of 
the disease can be blocked by the administration of 
corticosteroids [55]. 
Thus, our observations give further support to the 
hypothesis of an immunodysregulation as the under-
lying pathogenetical principle of sarcoidosis. 
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